Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Actinic Keratosis Treatment Market

Actinic Keratosis Treatment Market - By Therapy (Photodynamic Therapy, Surgery, Topical), By Drug Class (NSAIDs, Nucleoside Metabolic Inhibitor), By End-use (Hospitals & Oncology Centers, Dermatology Clinics) & Forecast 2023 - 2032

  • Report ID: GMI5859
  • Published Date: May 2023
  • Report Format: PDF

Actinic Keratosis Treatment Market Size

Actinic Keratosis Treatment Market size accounted for USD 5.5 billion in 2022 and is estimated to grow at 5.5% to reach USD 9.7 billion by 2032. Rising prevalence of actinic keratosis coupled with growing demand for minimally invasive procedures.

Actinic Keratosis Treatment Market

For instance, according to American Academy of Dermatology Association 2019 report, more than 40 million Americans develop actinic keratoses (AKs) each year. Thus, increase in the prevalence of actinic keratosis is propelling the demand for minimally invasive procedures such as photodynamic therapy, thereby driving the market growth. Also, growing awareness pertaining to actinic keratosis and various strategic initiatives undertaken by key market players is expected to propel the market progression.

Actinic keratosis (AK) refers to a precancerous skin condition characterized by rough, scaly patches or lesions on areas of the body such as such as the face, scalp, ears, and hands that have been exposed to the sun. It is primarily caused by long-term ultraviolet (UV) radiation exposure from the sun or tanning beds. AK is considered a pre-malignant condition, meaning that if left untreated, it has the potential to progress into a type of skin cancer known as squamous cell carcinoma.

COVID-19 Impact

The COVID-19 pandemic severely impacted the global economies with all the sectors witnessing a significant slump during 2020. The healthcare sector was one of the most severely impacted sectors during the pandemic owing to tremendous pressure on the healthcare systems to contain the spread of infection. Increasing number of COVID-19 cases lead to a delay in non-essential procedures including various dermatological procedures including actinic keratosis treatment.

Also, several local and national regulatory bodies-imposed lockdowns, restricting the movement of people and goods. Thus, imposed lockdowns lead to disruption of supply chain and affected the availability of actinic keratosis treatment medications and equipment. Thus, significant delays in obtaining topical medications and actinic keratosis treatment negatively impacted the market growth trajectory.

Actinic Keratosis Treatment Market Trends

Increasing number of drug approvals and the emergence of novel therapies is expected to boost market growth. For instance, in 2021, Biofrontera AG received FDA approval for its new BF-RhodoLED XL, used in combination with Ameluz for the treatment of mild and moderate actinic keratoses on the face and scalp. Similarly, in June 2020, Sun Pharmaceutical Industries Ltd received FDA approval for its LEVULAN KERASTICK, a photodynamic therapy medicine for use on the upper extremities. Thus, approval of new drugs and therapies for actinic keratosis management has expanded the range of treatment options available to healthcare providers, enhancing the effectiveness and outcomes for patients.

Actinic Keratosis Treatment Market Restrain

Actinic keratosis (AK) treatment options come with certain risks and side effects that may significantly impede the Actinic keratosis treatment industry growth. Treatments such as topical medications, cryotherapy, photodynamic therapy and surgical removal may possess risks such as skin irritation, redness, itching or discomfort at the treatment site.

Additionally, some treatments may result in temporary skin discoloration, scarring and infection. These potential side effects can impact patient satisfaction and adherence to treatment regimens. Furthermore, availability of alternative treatments such as generic medicine and availability of over-the-counter products and home remedies may impede the demand for prescription-based AK treatments.

Actinic Keratosis Treatment Market Analysis

Actinic Keratosis Treatment Market Size, By Therapy, 2021 - 2032 (USD Billion)

By therapy, the actinic keratosis treatment market is classified into photodynamic therapy, surgery and topical medications. The topical medications segment accounted over 49% of the market share in 2022 and is projected to witness robust growth over the analysis timeframe. Topical medications offer the ability to treat multiple AK lesions simultaneously, making them suitable for widespread or field treatment. Topical medications such as 5-fluorouracil (5-FU), imiquimod are applied directly to the affected areas of the skin, offering targeted therapy. Also, topical treatments are non-invasive and generally most preferred, as they offer convenience and minimal disruption to patients' daily lives.

Global Actinic Keratosis Treatment Market Revenue Share, By Drug Class, (2022)

Based on drug class, the market is segmented into NSAIDs, nucleoside metabolic inhibitor, immune response modifiers and photoenhancers. The nucleoside metabolic inhibitor is expected to register USD 3.1 billion in 2032. High segmental development is owing to the convenience of topical application that allows targeted delivery, minimizing systemic exposure to bloodstream and avoid potential side effects. Nucleoside metabolic inhibitor specifically target AK cell growth and proliferation by inhibiting nucleoside processes, leading to lesion regression. Also, clinical studies demonstrate their efficacy in reducing AK lesions, making them a beneficial option for managing actinic keratosis.

Actinic keratosis treatment market by end-use is market is divided into hospitals & oncology centers, dermatology clinics, homecare and others. The hospitals & oncology centers accounted for significant market proportion in 2022 and is expected to grow at 5.7% throughout the forecast period. Hospitals & oncology centers offer a wide range of treatment options for actinic keratosis including surgical interventions, cryotherapy, topical medications, photodynamic therapy among others.

Also, availability of multiple treatment alternatives allows healthcare providers to opt for most appropriate, suitable approach based on factors such as lesion characteristics, patient preferences and medical considerations. Furthermore, availability of skilled healthcare professionals, advanced healthcare infrastructure among others is projected to boost the market revenue.

 U.S. Actinic Keratosis Treatment Market Size, 2020 – 2032 (USD Million)

North America actinic keratosis treatment market accounted for 41.6% business share in 2022 and is anticipated to grow at considerable progress rate during the forecast timeframe. Increasing prevalence of actinic keratosis coupled with well-established healthcare infrastructure is expected to boost the actinic keratosis treatment in the North America region. Furthermore, growing awareness pertaining to various risks associated with sun exposure and regular skin examinations will significantly proliferate the market growth. Additionally, presence of key market players, introduction of innovative therapies and favorable reimbursement policies and insurance coverage for AK treatments in North America region is estimated to spur the market expansion.

Actinic Keratosis Treatment Market Share

Major market players operating in the actinic keratosis treatment market include

  • Sun Pharmaceutical Industries Ltd
  • Galderma S.A.
  • Biofrontera AG
  • Almirall, S.A.

These industry players majorly adopt various strategies including collaborations, acquisitions, mergers, and partnerships to create a global footprint and sustain market competition.

Actinic Keratosis Treatment Industry News:

  • In December 2022, Biofrontera AG commercially launched AMELUZ in Finland. This product launch can be used in line with the European approval for the treatment of actinic keratoses and basal cell carcinoma with the BF-RhodoLED lamp as part of conventional photodynamic therapy or as daylight therapy. This strategy helped the company enhance its product offerings as well as strengthen its geographical presence in the Europe region.
  • In December 2020, Almirall received FDA approval for Klisyri (tirbanibulin), a new innovative topical treatment for actinic keratosis. This product approval helped the company to enhance its actinin keratosis product portfolio and reach untap economies, thereby increase customer base.

The actinic keratosis treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments:

Click here to Buy Section of this Report

By Therapy

  • Photodynamic Therapy
  • Surgery
  • Topical Medications

By Drug Class

  • NSAIDs
  • Nucleoside Metabolic Inhibitor
  • Immune Response Modifiers
  • Photoenhancers

By End-use

  • Hospitals and Oncology Centers
  • Dermatology Clinics
  • Homecare
  • Others

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Poland
    • Sweden
    • The Netherlands
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Indonesia
    • Philippines
    • Malaysia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Columbia
    • Chile
    • Peru
    • Rest of Latin America
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Turkey
    • Iran
    • Rest of MEA


Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market for actinic keratosis treatment accounted for USD 5.5 billion in 2022 and is estimated to grow at 5.5% CAGR during 2023 to 2032. Rising prevalence of actinic keratosis, coupled with growing demand for minimally invasive procedures is expected to boost the market growth.

The topical medications segment accounted over 49% market share in 2022 and is projected to witness robust growth through 2032, owing to the ability of topical medications to treat multiple AK lesions simultaneously, making them suitable for widespread or field treatment.

North America accounted for 41.6% share in actinic keratosis treatment market in 2022 and is anticipated to grow at considerably over 2023-2032, backed by well-established healthcare infrastructure in the region, along with growing awareness pertaining to various risks associated with sun exposure and regular skin examinations.

Sun Pharmaceutical Industries Ltd, Galderma S.A., Biofrontera AG, Almirall, S.A. among others.

Actinic Keratosis Treatment Market Scope

Buy Now

Premium Report Details

  • Base Year: 2022
  • Companies covered: 12
  • Tables & Figures: 296
  • Countries covered: 34
  • Pages: 150
 Download Free Sample